Literature DB >> 15057874

The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.

Natalia A Ignatenko1, Hui Zhang, George S Watts, Bethany A Skovan, David E Stringer, Eugene W Gerner.   

Abstract

Mutation of the Kirsten-ras (Ki-ras) proto-oncogene occurs frequently in colorectal cancers. alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), inhibits Ki-ras transformation and colon tumorigenesis in carcinogen-treated animal models by mechanisms yet to be elucidated. Caco-2 cells transfected with an activated Ki-ras, but not parental cells, formed tumors in severe combined immunodeficient (SCID) mice. DFMO treatment (2% in drinking water) prevented tumor growth. Gene expression profiling was performed to identify Ki-ras-and DFMO-dependent patterns of gene expression. Microarray results were validated with real-time or semi-quantitative RT-PCR and/or Western blot analysis. Genes upregulated in Caco-2 cells expressing an activated Ki-ras encoded cytoskeletal-, transport-, protease-, and gap junction-associated proteins. These genes are important for normal development and maintenance of colonic epithelial tissue. Caco-2 cells transfected with an activated Ki-ras displayed increased expression of the integrin alpha 1 (INGA1) and enhanced cell migration on laminin. These parameters were unaffected by DFMO, but Ki-ras-dependent migration was inhibited by INGA1 antibodies. Other Ki-ras-dependent, but DFMO-independent, genes included transglutaminase (TGase) and kallikrein 6 (KLK6). Ki-ras-transfected cells also expressed increased levels of connexin43 (Cx43) (RNA and protein), tight junction protein, and endothelin 1. DFMO reversed these increases. The results indicated that the Ki-ras oncogene caused changes in experimental cell migration and cell-cell communication genes and that some of these changes could be reversed by DFMO. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057874     DOI: 10.1002/mc.20008

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  19 in total

Review 1.  DFMO: targeted risk reduction therapy for colorectal neoplasia.

Authors:  Christina M Laukaitis; Eugene W Gerner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

2.  Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc.

Authors:  Upal K Basu Roy; Rebecca S Henkhaus; Natalia A Ignatenko; Jessica Mora; Kimberly E Fultz; Eugene W Gerner
Journal:  Mol Carcinog       Date:  2008-12       Impact factor: 4.784

3.  Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck.

Authors:  Julia Thierauf; Johannes A Veit; Jochen K Lennerz; Stephanie E Weissinger; Annette Affolter; Johannes Döscher; Christoph Bergmann; Andreas Knopf; Jennifer Grünow; Lisa Grünmüller; Cornelia Mauch; Peter K Plinkert; Thomas K Hoffmann; Jochen Hess
Journal:  Head Neck Pathol       Date:  2016-11-14

4.  Coelomic fluid: a complimentary biological medium to assess sub-lethal endosulfan exposure using ¹H NMR-based earthworm metabolomics.

Authors:  Jimmy Yuk; Myrna J Simpson; André J Simpson
Journal:  Ecotoxicology       Date:  2012-03-27       Impact factor: 2.823

5.  Identification and characterization of a diamine exporter in colon epithelial cells.

Authors:  Takeshi Uemura; Hagit F Yerushalmi; George Tsaprailis; David E Stringer; Kirk E Pastorian; Leo Hawel; Craig V Byus; Eugene W Gerner
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

Review 6.  Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.

Authors:  Eugene W Gerner; Elizabeth Bruckheimer; Alfred Cohen
Journal:  J Biol Chem       Date:  2018-10-24       Impact factor: 5.157

7.  Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.

Authors:  Upal K Basu Roy; Rebecca S Henkhaus; Fotios Loupakis; Chiara Cremolini; Eugene W Gerner; Natalia A Ignatenko
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

8.  Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Authors:  Rebecca S Henkhaus; Eugene W Gerner; Natalia A Ignatenko
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

9.  Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.

Authors:  Ritu Pandey; Muhan Zhou; Yuliang Chen; Dalila Darmoul; Conner C Kisiel; Valentine N Nfonsam; Natalia A Ignatenko
Journal:  Genes (Basel)       Date:  2021-05-16       Impact factor: 4.096

10.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.

Authors:  K Oikonomopoulou; L Li; Y Zheng; I Simon; R L Wolfert; D Valik; M Nekulova; M Simickova; T Frgala; E P Diamandis
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.